Rankings
▼
Calendar
CTMX Q3 2016 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
CTMX
CytomX Therapeutics, Inc.
$827M
Q3 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3M
Gross Profit
$3M
100.0% margin
Operating Income
-$15M
-431.8% margin
Net Income
-$15M
-424.5% margin
EPS (Diluted)
$-0.40
QoQ Revenue Growth
+11.6%
Cash Flow
Operating Cash Flow
-$14M
Free Cash Flow
-$15M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$193M
Total Liabilities
$103M
Stockholders' Equity
$89M
Cash & Equivalents
$60M
← FY 2016
All Quarters
Q4 2016 →